WO2013088272A1 - Pharmaceutical composition comprising esomeprazole magnesium dihydrate - Google Patents
Pharmaceutical composition comprising esomeprazole magnesium dihydrate Download PDFInfo
- Publication number
- WO2013088272A1 WO2013088272A1 PCT/IB2012/056089 IB2012056089W WO2013088272A1 WO 2013088272 A1 WO2013088272 A1 WO 2013088272A1 IB 2012056089 W IB2012056089 W IB 2012056089W WO 2013088272 A1 WO2013088272 A1 WO 2013088272A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- esomeprazole magnesium
- pharmaceutical composition
- composition
- magnesium dihydrate
- wet granulated
- Prior art date
Links
- DBOUSUONOXEWHU-VCKZSRROSA-N magnesium;5-methoxy-2-[(s)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide;dihydrate Chemical compound O.O.[Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C DBOUSUONOXEWHU-VCKZSRROSA-N 0.000 title claims abstract description 46
- 229960000914 esomeprazole magnesium dihydrate Drugs 0.000 title claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- KWORUUGOSLYAGD-YPPDDXJESA-N esomeprazole magnesium Chemical compound [Mg+2].C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-YPPDDXJESA-N 0.000 claims abstract description 28
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 239000002552 dosage form Substances 0.000 claims abstract description 12
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 57
- -1 alkyl ketone Chemical class 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 22
- 229920001577 copolymer Polymers 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 13
- 230000001476 alcoholic effect Effects 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 239000008185 minitablet Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 238000005550 wet granulation Methods 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 239000007894 caplet Substances 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 claims description 2
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 210000004211 gastric acid Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 13
- 239000001993 wax Substances 0.000 description 13
- 239000011162 core material Substances 0.000 description 9
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229960004770 esomeprazole Drugs 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
- 229920002678 cellulose Chemical class 0.000 description 6
- 239000001913 cellulose Chemical class 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229960000197 esomeprazole magnesium Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 5
- 159000000003 magnesium salts Chemical class 0.000 description 5
- 229960000381 omeprazole Drugs 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 208000007107 Stomach Ulcer Diseases 0.000 description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000001069 triethyl citrate Substances 0.000 description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 4
- 235000013769 triethyl citrate Nutrition 0.000 description 4
- 229940117958 vinyl acetate Drugs 0.000 description 4
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 3
- 238000007614 solvation Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940033134 talc Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229920003072 Plasdone™ povidone Polymers 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000011418 maintenance treatment Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000004200 microcrystalline wax Substances 0.000 description 2
- 235000019808 microcrystalline wax Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 235000019809 paraffin wax Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QHZLMUACJMDIAE-SFHVURJKSA-N 1-hexadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO QHZLMUACJMDIAE-SFHVURJKSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- NVPAEDDMRNJJJX-UHFFFAOYSA-N 2,3-dihydroxypropyl dec-2-enoate Chemical compound CCCCCCCC=CC(=O)OCC(O)CO NVPAEDDMRNJJJX-UHFFFAOYSA-N 0.000 description 1
- RRZWKUGIZRDCPB-UHFFFAOYSA-N 2,3-dihydroxypropyl hexanoate Chemical compound CCCCCC(=O)OCC(O)CO RRZWKUGIZRDCPB-UHFFFAOYSA-N 0.000 description 1
- FMKIFJLNOGNQJR-UHFFFAOYSA-N 2,3-dihydroxypropyl tridec-2-enoate Chemical compound CCCCCCCCCCC=CC(=O)OCC(O)CO FMKIFJLNOGNQJR-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VKNASXZDGZNEDA-UHFFFAOYSA-N 2-cyanoethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC#N VKNASXZDGZNEDA-UHFFFAOYSA-N 0.000 description 1
- SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical class CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WXBXVVIUZANZAU-UHFFFAOYSA-N 2E-decenoic acid Natural products CCCCCCCC=CC(O)=O WXBXVVIUZANZAU-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000012164 animal wax Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000012179 bayberry wax Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012174 chinese wax Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229920001531 copovidone Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- KFEVDPWXEVUUMW-UHFFFAOYSA-N docosanoic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 KFEVDPWXEVUUMW-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074049 glyceryl dilaurate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 239000010512 hydrogenated peanut oil Substances 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000012182 japan wax Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229940112641 nexium Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012176 shellac wax Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical compound CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- MAYCICSNZYXLHB-UHFFFAOYSA-N tricaproin Chemical compound CCCCCC(=O)OCC(OC(=O)CCCCC)COC(=O)CCCCC MAYCICSNZYXLHB-UHFFFAOYSA-N 0.000 description 1
- 150000004684 trihydrates Chemical group 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Definitions
- the present invention relates to a wet granulated pharmaceutical composition
- a wet granulated pharmaceutical composition comprising esomeprazole magnesium dihydrate with one or more pharmaceutical excipients, wherein the dosage form is essentially free of esomeprazole magnesium trihydrate.
- Esomeprazole is the S-isomer of omeprazole
- Esomeprazole magnesium is a proton pump inhibitor used for the treatment of conditions where a reduction in gastric acid secretion is required.
- the conditions requiring reduction of gastric acid secretion may comprise, but not limited to treatment of gastroesophageal reflux disease, maintenance treatment of patients with reflux esophagitis, nonerosive reflux disease (NERD) (i.e. heartburn and regurgitation), healing of Nonsteroidal anti-inflammatory drug (NSAID) -associated gastric ulcers, reduction of risk of NSAID-associated gastric ulcers treatment of pathological hypersecretory conditions, including Zollinger-Ellison, Syndrome, Helicobacter pylori (H. pylori) eradication.
- the magnesium salt is a white to slightly colored crystalline powder. It is marketed under trade name of Nexium® delayed release dosage form and contains esomeprazole magnesium trihydrate. Esomeprazole magnesium trihydrate contains 3 moles of water of solvation and is slightly soluble in water. The structural formula of esomeprazole magnesium trihydrate is: Esomeprazole magnesium dihydrate is a moisture sensitive drug. Presence of moisture leads to conversion of esomeprazole magnesium dihydrate form to esomeprazole magnesium trihydrate form during storage or shelf life of the pharmaceutical dosage form. It is understood that for the development of formulation of any active pharmaceutical ingredient, the chemical stability, solid- state stability, and shelf life of the active pharmaceutical ingredient are important properties. The compositions containing active pharmaceutical ingredient, should be capable of being effectively stored over appreciable period of time, without exhibiting a significant change in the physico-chemical characteristics of the active pharmaceutical ingredient.
- the inventors of the present invention have found that when esomeprazole magnesium dihydrate is processed or formulated in presence of water, it gets converted to esomeprazole magnesium trihydrate. Further, use of alcoholic solvents lead to conversion of esomeprazole magnesium dihydrate to amorphous form or exhibited discoloration due to degradation of esomeprazole magnesium dihydrate.
- U.S. Patent No. 7,41 1 ,070 discloses magnesium salt of S-omeprazole trihydrate.
- the prior art discloses several processes for preparing pure and stable form of esomeprazole magnesium dihydrate essentially free of esomeprazole magnesium trihydrate.
- a wet granulated pharmaceutical dosage form comprising esomeprazole magnesium dihydrate with one or more pharmaceutical excipients, wherein the dosage form is substantially free of esomeprazole magnesium trihydrate.
- step (b) granulating the mixture prepared in step (a) by wet granulation process using a non-aqueous, non-alcoholic solvent as granulating liquid;
- composition is substantially free of esomeprazole magnesium trihydrate.
- step (b) granulating the mixture prepared in step (a) by wet granulation process using a non-aqueous, non-alcoholic solvent as granulating liquid;
- step (c) drying the granules prepared in step (b);
- composition is substantially free of esomeprazole magnesium trihydrate.
- process of preparing a pharmaceutical composition of esomeprazole magnesium dihydrate which process comprises a step of coating esomeprazole magnesium dihydrate on an inert core, wherein the composition is substantially free of esomeprazole magnesium trihydrate.
- a wet granulated, pharmaceutical composition comprising esomeprazole magnesium dihydrate with one or more pharmaceutical excipients, wherein the composition exhibits controlled release, extended release, delayed release of esomeprazole magnesium dihydrate, and characterized in that the composition is substantially free of esomeprazole magnesium trihydrate.
- Figure 1 XRD of Esomeprazole magnesium trihydrate.
- Figure 3 XRD of Esomeprazole magnesium dihydrate composition of Example 1 .
- Figure 3(A) XRD of Esomeprazole magnesium dihydrate composition of Example 1 after storage at 40°C at 75% RH for 3 months in 60cc HDPE container with CRC & 2 silica gel canister.
- compositions comprising esomeprazole magnesium dihydrate by wet granulation technique
- esomeprazole magnesium dihydrate is highly unstable and readily converts to esomeprazole magnesium trihydrate when water or water like aqueous based solvents are used during formulation process.
- the present inventors surprisingly found that when non-aqueous, non-alcoholic solvents were used for wet granulation process, the granules obtained had improved the stability of esomeprazole magnesium dihydrate during formulation and shelf life of dosage form. Further the compositions so obtained are essentially free of esomeprazole trihydrate throughout the shelf life of the composition.
- composition of the present invention not only prevents the physical transformation of esomeprazole magnesium dihydrate to esomeprazole magnesium trihydrate during formulation process but also maintains its stability during storage.
- Solvents suitable for the process of the present invention are those known to ordinary skilled in the art and includes but not limited to one or more di-lower alkyl ketone, example acetone, chloroform, dimethyl acetamide (DMA), dimethyl sulfoxide (DMSO), ether, diethyl ether etc.
- DMA dimethyl acetamide
- DMSO dimethyl sulfoxide
- the composition comprises one or more layers of esomeprazole magnesium dihydrate coated on cores.
- the core material used is water-soluble inert core comprises of sugar spheres.
- the water-soluble inert core can comprise hydroxypropyl methylcellulose, microcrystalline cellulose, starch or mixtures thereof.
- composition exhibits extended release, modified release, controlled release or delayed release of esomeprazole magnesium dihydrate.
- composition is further coated with one or more functional (e.g. enteric coating) or non-functional layers (barrier or film-coating).
- functional e.g. enteric coating
- non-functional layers e.g. film-coating
- the coating layer can be a film coat, seal coat, sub-coat, delayed release coat or an enteric release coat.
- the coating can be carried out by using fluidized bed processor,therapist, spray dryer, or any other suitable coating techniques known in the art.
- the pharmaceutical compositions may be formulated in the form of pellets, tablets, capsules, granules, beads, caplets, disc, pills, sachet, spheroids, mini-tablets, granules in a capsule, and beads and/or mini-tablets in a capsule.
- composition of the invention further may comprise pharmaceutically acceptable excipients selected from one or more of binders, glidants, lubricants, fillers, plasticizers, lubricants, etc.
- binders include, starch, gums, pregelatinized starch, povidone, povidone derivatives, crospovidone, copolymer of N-vinyl-2- pyrrolidone and vinyl acetate, stearic acid, polyvinyl pyrrolidone (PVP), copovidone, cellulose derivatives, such as hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), and carboxymethyl cellulose (CMC) and their salts.
- PVP polyvinyl pyrrolidone
- HPMC hydroxypropylmethyl cellulose
- HPC hydroxypropyl cellulose
- CMC carboxymethyl cellulose
- Suitable binder for the present invention includes copolymer of N-vinyl-2- pyrrolidone and vinyl acetate or povidone derivatives.
- Suitable fillers may include one or more of saccharose, glucose, fructose, maltose, maltitol, mannitol, dextrins such as maltodextrins; xylitol, sorbitol, microcrystalline cellulose, titanium dioxide, calcium phosphate, calcium sulfate, kaolin, dry starch, powdered sugar, or silicates such as magnesium aluminium silicate.
- Suitable pharmaceutically acceptable plasticizers comprise of dioctylphthalate, dibutyl phthalate, benzylptyl phthalate, triethylcitrate or polyethelene glycol.
- Suitable lubricant may include one or more of, magnesium stearate, zinc stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, glyceryl behenate, talc, etc.
- Suitable disintegrant may include one or more of, starch, croscarmellose sodium, crospovidone, sodium starch glycolate, etc.
- Suitable glidant may include one or more of, colloidal silicon dioxide, talc or cornstarch, etc.
- Suitable coating polymers selected from the group consisting of one or more of cellulose derivatives; polyhydric alcohols; saccharides, gums and derivatives thereof; vinyl derivatives, polymers, copolymers or mixtures thereof; maleic acid copolymers; polyalkylene oxides or copolymers thereof; acrylic acid polymers and acrylic acid derivatives; or any combinations thereof.
- Cellulose derivatives include, ethyl cellulose, methylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl ethylcellulose, carboxymethylethyl cellulose, carboxy ethylcellulose, carboxymethyl hydroxyethylcellulose, hydroxyethylmethyl carboxymethyl cellulose, hydroxyethyl methyl cellulose, carboxymethyl cellulose (CMC), methylhydroxyethyl cellulose, methylhydroxypropyl cellulose, carboxymethyl sulfoethyl cellulose, sodium carboxymethyl cellulose, or combinations thereof.
- Polyhydric alcohols include, polyethylene glycol (PEG) or polypropylene glycol or any combinations thereof.
- Saccharides, gums and their derivatives include, dextrin, polydextrin, dextran, pectin and pectin derivatives, alginic acid, sodium alginate, polygalacturonic acid, xylan, arabinoxylan, arabinogalactan, starch, hydroxypropyl starch, amylose and amylopectin, CMC agar; guar gum, locust bean gum, xanthan gum, karaya gum, tragacanth, carrageenan, acacia gum, arabic gum or gellan gum or the like; or any combinations thereof.
- Vinyl derivatives, polymers, copolymers or mixtures thereof include, polyvinyl acetate, polyvinyl alcohol, mixture of polyvinyl acetate (8 parts w/w) and polyvinylpyrrolidone (2 parts w/w) (Kollidon SR), copolymers of vinyl pyrrolidone, vinyl acetate copolymers, polyvinylpyrrolidone (PVP); or combinations thereof.
- Polyalkylene oxides or copolymers thereof include, polyethylene oxide, polypropylene oxide, poly (oxyethylene)-poly (oxypropylene) block copolymers (poloxamers) or combinations thereof.
- Maleic acid copolymers include, vinylacetate, maleic acid anhydride copolymer, styrene, maleic acid anhydride copolymer, styrene, maleic acid monoester copolymer, vinylmethylether, maleic acid anhydride copolymer, ethylene, maleic acid anhydride copolymer, vinylbutyiether, maleic acid anhydride copolymer, acrylonitrile, methyl acrylate, ethyl acrylate, maleic acid anhydride copolymer, butyl acrylate, styrene, maleic acid anhydride copolymer or the like or any combinations thereof.
- Suitable acrylic acid polymers include any suitable polyacrylic acid polymers or carboxyvinyl polymers such as those available under the brand name carbopol, Eudagrit.
- Pharmaceutically acceptable acrylic polymer may include one or more, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid) (anhydride), methyl methacrylate, polymethacrylate, poly(methyl methacrylate), poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid anhydride), and glycidyl methacrylate.
- Non-polymeric rate controlling excipient is selected
- Waxes are esters of fatty acids with long chain monohydric alcohols. Natural waxes are often mixtures of such esters, and may also contain hydrocarbons. Waxes employed in the present invention include, but are not limited to, natural waxes (such as animal waxes, vegetable waxes, and petroleum waxes, paraffin waxes, microcrystalline waxes, petrolatum waxes, mineral waxes), and synthetic waxes.
- natural waxes such as animal waxes, vegetable waxes, and petroleum waxes, paraffin waxes, microcrystalline waxes, petrolatum waxes, mineral waxes
- synthetic waxes such as synthetic waxes.
- Specific examples include, but are not limited to spermaceti wax, carnauba wax, Japan wax, bayberry wax, flax wax, beeswax, yellow wax, Chinese wax, shellac wax, lanolin wax, sugarcane wax, candelilla wax, castor wax, paraffin wax, microcrystalline wax, petrolatum wax, carbowax, and the like, or mixtures thereof.
- waxes are monoglyceryl esters, diglyceryl esters, or glyceryl esters (glycerides) and derivatives or mixtures thereof formed from a fatty acid having from about 10 to about 22 carbon atoms and glycerol, wherein one or more of the hydroxyl groups of glycerol are substituted by a fatty acid.
- Glycerides employed in the present invention include, but are not limited to, glyceryl monostearate, glyceryl distearate, glyceryl tristearate, glyceryl dipalmitate, glyceryl tripalmitate, glyceryl monopalmitate, glyceryl palmitostearate, glyceryl dilaurate, glyceryl trilaurate, glyceryl monolaurate, glyceryl didocosanoate, glyceryl tridocosanoate, glyceryl monodocosanoate, glyceryl monocaproate, glyceryl dicaproate, glyceryl tricaproate, glyceryl monomyristate, glyceryl dimyristate, glyceryl trimyristate, glyceryl monodecenoate, glyceryl didecenoate, glyceryl tridecen
- Fatty acids include, but are not limited to, hydrogenated palm kernel oil, hydrogenated peanut oil, hydrogenated palm oil, hydrogenated rapeseed oil, hydrogenated rice bran oil, hydrogenated soybean oil, hydrogenated sunflower oil, hydrogenated castor oil (Lubritab), hydrogenated cottonseed oil, and mixtures thereof.
- Other fatty acids include, but are not limited to, decenoic acid, docosanoic acid, stearic acid, palmitic acid, lauric acid, myristic acid, etc. or mixtures thereof.
- Long chain monohydric alcohols include, but are not limited to, cetyl alcohol, or stearyl alcohol or mixtures thereof.
- wet granulation refers to process involving introduction of binder and solvent to the pharmaceutical powder.
- esomeprazole magnesium dihydrate refers to magnesium salt of esomeprazole having molecular formula C 34 H36MgN6O6S 2 -2H 2 O and comprises 2 moles of water of solvation.
- esomeprazole magnesium trihydrate refers to magnesium salt of esomeprazole having molecular formula C 34 H36MgN6O6S 2 -3H 2 O and comprises 3 moles of water of solvation.
- essentially free of esomeprazole magnesium trihydrate means that there is presence less than 0.001 %w/w of trihydrate form of esomeprazole magnesium.
- pharmaceutical excipients refers to binders, plasticizer, fillers, lubricants, disintegrants, surfactants and glidants.
- pharmaceutical dosage form or “pharmaceutical composition” refers to tablets, capsules, granules, beads, caplets, disc, pills, sachet, spheroids, minitablets, granules in a capsule, beads in a capsule and mini-tablets in a capsule.
- inert core includes core that water soluble or water-swellable inert core.
- 'inlayed tablet' refers to a type of a layered tablet in which instead of the core tablet being completely surrounded by a coating, the top surface is completely exposed.
- composition of the present invention may be used for the treatment of various conditions requiring reduction in gastric acid secretion.
- Such conditions includes, but are not limited to gastroesophageal reflux disease, maintenance treatment of patients with reflux esophagitis, non-erosive reflux disease (NERD) (i.e. heartburn and regurgitation), Nonsteroidal anti-inflammatory drug (NSAID) associated gastric ulcers, risk of NSAID-associated gastric ulcers treatment of pathological hypersecretory conditions (including Zollinger-Ellison Syndrome), Helicobacter pylori (H. pylori) infection.
- GED non-erosive reflux disease
- NSAID Nonsteroidal anti-inflammatory drug
- Example 1 Esomeprazole magnesium dihydrate granules
- Esomeprazole magnesium was sifted along with mannitol.
- PEG 6000 was melted by gentle, heating and acetone was added to it followed by addition of Plasdone S 630. Spray the molten mixture on the powder mixture to get granules.
- Granules were lubricated sodium stearyl fumarate.
- Granules were coated with seal coat. Further, enteric coat was applied.
- Esomeprazole magnesium was sifted along with mannitol.
- PEG 6000 was melted by gentle, heating and Acetone was added to it followed by addition of Plasdone S 630.
- the molten mixture was sprayed on the powder mixture to get granules.
- Granules were lubricated with sodium stearyl fumarate and were coated with seal coat. Further, enteric coat was applied. Further granules were lubricated with talc before compression into tablet dosage form.
- Example 4 Characterization of Esomeprazole magnesium dihydrate formulation of Example 1 using X-ray powder diffraction.
- Table 7 Esomeprazole magnesium dihydrate formulation of Example 1 packed in 60cc HDPE container with CRC & 2 silica gel canisters
- Example 1 The stability study results of the formulation of Example 1 indicates that, the it remains stable for a period of at least 3 months at 40 °C at 75% relative humidity, independent of the packaging. Further, total related substances were within the specified limits.
- Example 1 The formulation of Example 1 was subjected to dissolution study using USP Type II (Paddle) dissolution apparatus at 100rpm after storing the formulation over 3 months at 40 °C and 75% relative humidity.
- Table 9 Esomeprazole magnesium dihydrate formulation of Example 1 packed in 60cc HDPE container with CRC & 2 silica gel canisters
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a wet granulated pharmaceutical composition comprising esomeprazole magnesium dihydrate with one or more pharmaceutical excipients, wherein the dosage form is essentially free of esomeprazole magnesium trihydrate.
Description
PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE MAGNESIUM DIHYDRATE
Field Of The Invention
The present invention relates to a wet granulated pharmaceutical composition comprising esomeprazole magnesium dihydrate with one or more pharmaceutical excipients, wherein the dosage form is essentially free of esomeprazole magnesium trihydrate.
Background Of The Invention
Esomeprazole is the S-isomer of omeprazole Esomeprazole magnesium is a proton pump inhibitor used for the treatment of conditions where a reduction in gastric acid secretion is required. The conditions requiring reduction of gastric acid secretion may comprise, but not limited to treatment of gastroesophageal reflux disease, maintenance treatment of patients with reflux esophagitis, nonerosive reflux disease (NERD) (i.e. heartburn and regurgitation), healing of Nonsteroidal anti-inflammatory drug (NSAID) -associated gastric ulcers, reduction of risk of NSAID-associated gastric ulcers treatment of pathological hypersecretory conditions, including Zollinger-Ellison, Syndrome, Helicobacter pylori (H. pylori) eradication.
The magnesium salt is a white to slightly colored crystalline powder. It is marketed under trade name of Nexium® delayed release dosage form and contains esomeprazole magnesium trihydrate. Esomeprazole magnesium trihydrate contains 3 moles of water of solvation and is slightly soluble in water. The structural formula of esomeprazole magnesium trihydrate is:
Esomeprazole magnesium dihydrate is a moisture sensitive drug. Presence of moisture leads to conversion of esomeprazole magnesium dihydrate form to esomeprazole magnesium trihydrate form during storage or shelf life of the pharmaceutical dosage form. It is understood that for the development of formulation of any active pharmaceutical ingredient, the chemical stability, solid- state stability, and shelf life of the active pharmaceutical ingredient are important properties. The compositions containing active pharmaceutical ingredient, should be capable of being effectively stored over appreciable period of time, without exhibiting a significant change in the physico-chemical characteristics of the active pharmaceutical ingredient.
The inventors of the present invention have found that when esomeprazole magnesium dihydrate is processed or formulated in presence of water, it gets converted to esomeprazole magnesium trihydrate. Further, use of alcoholic solvents lead to conversion of esomeprazole magnesium dihydrate to amorphous form or exhibited discoloration due to degradation of esomeprazole magnesium dihydrate.
U.S. Patent No. 7,41 1 ,070 discloses magnesium salt of S-omeprazole trihydrate.
The prior art discloses several processes for preparing pure and stable form of esomeprazole magnesium dihydrate essentially free of esomeprazole magnesium trihydrate.
Thus, there existed a continuing need to develop new compositions with improved stability of the active ingredient, wherein the active ingredient is esomeprazole magnesium dihydrate which will not get convert to esomeprazole trihydrate in composition throughout the shelf life of the product.
None of the prior art however discloses a pharmaceutical composition comprising esomeprazole magnesium dihydrate, which is substantially free of esomeprazole magnesium trihydrate, which is safe and has an enhanced therapeutic effect over the existing individual drug therapy.
Summary of The Invention
In one general aspect of the invention, there is provided a wet granulated pharmaceutical dosage form comprising esomeprazole magnesium dihydrate with one or more pharmaceutical excipients, wherein the dosage form is substantially free of esomeprazole magnesium trihydrate.
In another general aspect of the invention, there is provided a process of preparing a pharmaceutical composition of esomeprazole magnesium dihydrate, which process comprises steps of:
(a) mixing esomeprazole magnesium dihydrate with a binder soluble in non aqueous non-alcoholic solvent for granulation, optionally along with one or more pharmaceutically acceptable excipients;
(b) granulating the mixture prepared in step (a) by wet granulation process using a non-aqueous, non-alcoholic solvent as granulating liquid;
(c) optionally, formulating the granules in a desired dosage form,
wherein the composition is substantially free of esomeprazole magnesium trihydrate.
In another general aspect of the invention, there is provided a process of preparing a pharmaceutical composition of esomeprazole magnesium dihydrate, which process comprises steps of:
(a) mixing esomeprazole magnesium dihydrate with a binder soluble in non aqueous non-alcoholic solvent for granulation, optionally along with one or more pharmaceutically acceptable excipients;
(b) granulating the mixture prepared in step (a) by wet granulation process using a non-aqueous, non-alcoholic solvent as granulating liquid;
(c) drying the granules prepared in step (b); and
(d) optionally formulating the granules in a desired dosage form,
wherein the composition is substantially free of esomeprazole magnesium trihydrate.
In another general aspect of the invention, there is provided a process of preparing a pharmaceutical composition of esomeprazole magnesium dihydrate, which process comprises a step of coating esomeprazole magnesium dihydrate on an inert core, wherein the composition is substantially free of esomeprazole magnesium trihydrate.
In another general aspect of the invention, there is provided a wet granulated, pharmaceutical composition comprising esomeprazole magnesium dihydrate with one or more pharmaceutical excipients, wherein the composition exhibits controlled release, extended release, delayed release of esomeprazole magnesium dihydrate, and characterized in that the composition is substantially free of esomeprazole magnesium trihydrate.
Brief Description of the Drawings
Figure 1 : XRD of Esomeprazole magnesium trihydrate.
Figure 2: XRD of Esomeprazole magnesium dihydrate.
Figure 3: XRD of Esomeprazole magnesium dihydrate composition of Example 1 . Figure 3(A): XRD of Esomeprazole magnesium dihydrate composition of Example 1 after storage at 40°C at 75% RH for 3 months in 60cc HDPE container with CRC & 2 silica gel canister.
Figure 3(B): XRD of Esomeprazole Magnesium Dihydrate composition of Examplel after storage at 40 °C at 75% RH for 3 months in Alu-Alu Blister pack.
Detailed Description of The Invention
The present inventors while formulating compositions comprising esomeprazole magnesium dihydrate by wet granulation technique discovered that esomeprazole magnesium dihydrate is highly unstable and readily converts to esomeprazole magnesium trihydrate when water or water like aqueous based solvents are used during formulation process.
The present inventors surprisingly found that when non-aqueous, non-alcoholic solvents were used for wet granulation process, the granules obtained had improved the stability of esomeprazole magnesium dihydrate during formulation and shelf life of dosage form. Further the compositions so obtained are essentially free of esomeprazole trihydrate throughout the shelf life of the composition.
Thus, the composition of the present invention not only prevents the physical transformation of esomeprazole magnesium dihydrate to esomeprazole magnesium trihydrate during formulation process but also maintains its stability during storage.
Solvents suitable for the process of the present invention are those known to ordinary skilled in the art and includes but not limited to one or more di-lower alkyl ketone, example acetone, chloroform, dimethyl acetamide (DMA), dimethyl sulfoxide (DMSO), ether, diethyl ether etc.
In an embodiment, the composition comprises one or more layers of esomeprazole magnesium dihydrate coated on cores.
The core material used is water-soluble inert core comprises of sugar spheres. The water-soluble inert core can comprise hydroxypropyl methylcellulose, microcrystalline cellulose, starch or mixtures thereof.
In a further embodiment the composition exhibits extended release, modified release, controlled release or delayed release of esomeprazole magnesium dihydrate.
In a further embodiment, the composition is further coated with one or more functional (e.g. enteric coating) or non-functional layers (barrier or film-coating).
In another embodiment, the coating layer can be a film coat, seal coat, sub-coat, delayed release coat or an enteric release coat.
In another embodiment, the coating can be carried out by using fluidized bed processor, glatt, spray dryer, or any other suitable coating techniques known in the art.
In another embodiment, the pharmaceutical compositions may be formulated in the form of pellets, tablets, capsules, granules, beads, caplets, disc, pills, sachet, spheroids, mini-tablets, granules in a capsule, and beads and/or mini-tablets in a capsule.
The pharmaceutical composition of the invention further may comprise pharmaceutically acceptable excipients selected from one or more of binders, glidants, lubricants, fillers, plasticizers, lubricants, etc.
The examples of suitable binders include, starch, gums, pregelatinized starch, povidone, povidone derivatives, crospovidone, copolymer of N-vinyl-2- pyrrolidone and vinyl acetate, stearic acid, polyvinyl pyrrolidone (PVP), copovidone, cellulose derivatives, such as hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), and carboxymethyl cellulose (CMC) and their salts.
Suitable binder for the present invention includes copolymer of N-vinyl-2- pyrrolidone and vinyl acetate or povidone derivatives.
Suitable fillers may include one or more of saccharose, glucose, fructose, maltose, maltitol, mannitol, dextrins such as maltodextrins; xylitol, sorbitol, microcrystalline cellulose, titanium dioxide, calcium phosphate, calcium sulfate, kaolin, dry starch, powdered sugar, or silicates such as magnesium aluminium silicate.
Suitable pharmaceutically acceptable plasticizers comprise of dioctylphthalate, dibutyl phthalate, benzylptyl phthalate, triethylcitrate or polyethelene glycol.
Suitable lubricant may include one or more of, magnesium stearate, zinc stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, glyceryl behenate, talc, etc.
Suitable disintegrant may include one or more of, starch, croscarmellose sodium, crospovidone, sodium starch glycolate, etc.
Suitable glidant may include one or more of, colloidal silicon dioxide, talc or cornstarch, etc.
Suitable coating polymers selected from the group consisting of one or more of cellulose derivatives; polyhydric alcohols; saccharides, gums and derivatives thereof; vinyl derivatives, polymers, copolymers or mixtures thereof; maleic acid copolymers; polyalkylene oxides or copolymers thereof; acrylic acid polymers and acrylic acid derivatives; or any combinations thereof.
Cellulose derivatives include, ethyl cellulose, methylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl ethylcellulose, carboxymethylethyl cellulose, carboxy ethylcellulose, carboxymethyl hydroxyethylcellulose, hydroxyethylmethyl carboxymethyl cellulose, hydroxyethyl methyl cellulose, carboxymethyl cellulose (CMC), methylhydroxyethyl cellulose, methylhydroxypropyl cellulose, carboxymethyl sulfoethyl cellulose, sodium carboxymethyl cellulose, or combinations thereof.
Polyhydric alcohols include, polyethylene glycol (PEG) or polypropylene glycol or any combinations thereof.
Saccharides, gums and their derivatives include, dextrin, polydextrin, dextran, pectin and pectin derivatives, alginic acid, sodium alginate, polygalacturonic acid, xylan, arabinoxylan, arabinogalactan, starch, hydroxypropyl starch, amylose and amylopectin, CMC agar; guar gum, locust bean gum, xanthan gum, karaya gum,
tragacanth, carrageenan, acacia gum, arabic gum or gellan gum or the like; or any combinations thereof.
Vinyl derivatives, polymers, copolymers or mixtures thereof include, polyvinyl acetate, polyvinyl alcohol, mixture of polyvinyl acetate (8 parts w/w) and polyvinylpyrrolidone (2 parts w/w) (Kollidon SR), copolymers of vinyl pyrrolidone, vinyl acetate copolymers, polyvinylpyrrolidone (PVP); or combinations thereof.
Polyalkylene oxides or copolymers thereof include, polyethylene oxide, polypropylene oxide, poly (oxyethylene)-poly (oxypropylene) block copolymers (poloxamers) or combinations thereof.
Maleic acid copolymers include, vinylacetate, maleic acid anhydride copolymer, styrene, maleic acid anhydride copolymer, styrene, maleic acid monoester copolymer, vinylmethylether, maleic acid anhydride copolymer, ethylene, maleic acid anhydride copolymer, vinylbutyiether, maleic acid anhydride copolymer, acrylonitrile, methyl acrylate, ethyl acrylate, maleic acid anhydride copolymer, butyl acrylate, styrene, maleic acid anhydride copolymer or the like or any combinations thereof.
Suitable acrylic acid polymers include any suitable polyacrylic acid polymers or carboxyvinyl polymers such as those available under the brand name carbopol, Eudagrit. Pharmaceutically acceptable acrylic polymer may include one or more, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic acid) (anhydride), methyl methacrylate, polymethacrylate, poly(methyl methacrylate), poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid anhydride), and glycidyl methacrylate.
Non-polymeric rate controlling excipient is selected from the group consisting of fat, wax, fatty acid, fatty acid ester, long chain monohydric alcohol or their ester or any combinations thereof.
Waxes are esters of fatty acids with long chain monohydric alcohols. Natural waxes are often mixtures of such esters, and may also contain hydrocarbons. Waxes employed in the present invention include, but are not limited to, natural waxes (such as animal waxes, vegetable waxes, and petroleum waxes, paraffin waxes, microcrystalline waxes, petrolatum waxes, mineral waxes), and synthetic waxes. Specific examples include, but are not limited to spermaceti wax, carnauba wax, Japan wax, bayberry wax, flax wax, beeswax, yellow wax, Chinese wax, shellac wax, lanolin wax, sugarcane wax, candelilla wax, castor wax, paraffin wax, microcrystalline wax, petrolatum wax, carbowax, and the like, or mixtures thereof.
Also some other type of waxes are monoglyceryl esters, diglyceryl esters, or glyceryl esters (glycerides) and derivatives or mixtures thereof formed from a fatty acid having from about 10 to about 22 carbon atoms and glycerol, wherein one or more of the hydroxyl groups of glycerol are substituted by a fatty acid. Glycerides employed in the present invention include, but are not limited to, glyceryl monostearate, glyceryl distearate, glyceryl tristearate, glyceryl dipalmitate, glyceryl tripalmitate, glyceryl monopalmitate, glyceryl palmitostearate, glyceryl dilaurate, glyceryl trilaurate, glyceryl monolaurate, glyceryl didocosanoate, glyceryl tridocosanoate, glyceryl monodocosanoate, glyceryl monocaproate, glyceryl dicaproate, glyceryl tricaproate, glyceryl monomyristate, glyceryl dimyristate, glyceryl trimyristate, glyceryl monodecenoate, glyceryl didecenoate, glyceryl tridecenoate, glyceryl behenate (compritol), polyglyceryl diisostearate, lauroyl macrogolglycerides (Gelucire), oleoyl macrogolglycerides, stearoyl macrogolglycerides, mixtures of monoglycerides and diglycerides of oleic acid (Peceol), or combinations thereof.
Fatty acids include, but are not limited to, hydrogenated palm kernel oil, hydrogenated peanut oil, hydrogenated palm oil, hydrogenated rapeseed oil,
hydrogenated rice bran oil, hydrogenated soybean oil, hydrogenated sunflower oil, hydrogenated castor oil (Lubritab), hydrogenated cottonseed oil, and mixtures thereof. Other fatty acids include, but are not limited to, decenoic acid, docosanoic acid, stearic acid, palmitic acid, lauric acid, myristic acid, etc. or mixtures thereof.
Long chain monohydric alcohols include, but are not limited to, cetyl alcohol, or stearyl alcohol or mixtures thereof.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
The term "wet granulation" refers to process involving introduction of binder and solvent to the pharmaceutical powder.
The term "esomeprazole magnesium dihydrate" refers to magnesium salt of esomeprazole having molecular formula C34H36MgN6O6S2-2H2O and comprises 2 moles of water of solvation.
The term "esomeprazole magnesium trihydrate" refers to magnesium salt of esomeprazole having molecular formula C34H36MgN6O6S2-3H2O and comprises 3 moles of water of solvation.
The term "essentially free of esomeprazole magnesium trihydrate" means that there is presence less than 0.001 %w/w of trihydrate form of esomeprazole magnesium.
The term "pharmaceutical excipients" refers to binders, plasticizer, fillers, lubricants, disintegrants, surfactants and glidants.
The term "pharmaceutical dosage form" or "pharmaceutical composition" refers to tablets, capsules, granules, beads, caplets, disc, pills, sachet, spheroids, minitablets, granules in a capsule, beads in a capsule and mini-tablets in a capsule.
The phrase "inert core," as used herein, includes core that water soluble or water-swellable inert core.
The term 'inlayed tablet' as used herein refers to a type of a layered tablet in which instead of the core tablet being completely surrounded by a coating, the top surface is completely exposed.
The composition of the present invention may be used for the treatment of various conditions requiring reduction in gastric acid secretion. Such conditions includes, but are not limited to gastroesophageal reflux disease, maintenance treatment of patients with reflux esophagitis, non-erosive reflux disease (NERD) (i.e. heartburn and regurgitation), Nonsteroidal anti-inflammatory drug (NSAID) associated gastric ulcers, risk of NSAID-associated gastric ulcers treatment of pathological hypersecretory conditions (including Zollinger-Ellison Syndrome), Helicobacter pylori (H. pylori) infection.
The present invention is further illustrated by the following examples which are provided merely to be exemplary of the invention and do not limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
Example 1 : Esomeprazole magnesium dihydrate granules
Table 1
Procedure:
Polethylene glycol and acetone were mixed with gentle heating. Esomeprazole was dispersed in the above mixture. The dispersion was then sprayed on the sugar sphere. The drug coated sugar spheres were then given seal coat of HPMC followed by enteric coat comprising of Eudagrit and plasticizers TEC (triethyl citrate) and PlasACRYL (glyceryl monostearate and triethyl citrate).
Example 2: Esomeprazole magnesium dihydrate mini-tablet
Table 2
Procedure:
Esomeprazole magnesium was sifted along with mannitol. PEG 6000 was melted by gentle, heating and acetone was added to it followed by addition of Plasdone S 630. Spray the molten mixture on the powder mixture to get granules. Granules
were lubricated sodium stearyl fumarate. Granules were coated with seal coat. Further, enteric coat was applied.
Example 3: Esomeprazole magnesium dihydrate tablet
Table 3
Procedure:
Esomeprazole magnesium was sifted along with mannitol. PEG 6000 was melted by gentle, heating and Acetone was added to it followed by addition of Plasdone S 630. The molten mixture was sprayed on the powder mixture to get granules. Granules were lubricated with sodium stearyl fumarate and were coated with seal
coat. Further, enteric coat was applied. Further granules were lubricated with talc before compression into tablet dosage form.
Example 4: Characterization of Esomeprazole magnesium dihydrate formulation of Example 1 using X-ray powder diffraction.
Table 4
Some additional very weak peaks found in the diffractogram have been omitted from Table 5 & 6.
Table 5
Positions and intensities of the major peaks in the XRP- diffractogram Of the formulation of magnesium salt of esomeprazole dihydrate after storage at 40 °C at 75% RH for 3 months in 60cc HDPE with CRC & 2 silica gel canister
d-value/°A Relative Intensity
15.3 vs
9.3 vs
7.6 vs
7.0 vs
6.8 vs
4.7 vs
4.5 vs
4.3 vs
3.6 vs
3.5 vs
3.1 vs
2.9 s
2.8 s
2.4 s
Table 6
Example 5: Stability study (Effect of Packaging)
Table 7: Esomeprazole magnesium dihydrate formulation of Example 1 packed in 60cc HDPE container with CRC & 2 silica gel canisters
Impurity (%)
Related Substances 40^/75%ΒΗ
Initial
1 M 2M 3M
Citizen Impurity A 0.003 0.019 0.025 0.025
Omprazole N-Oxide 0.000 0.007 0.01 1 0.000
Omeprazole Related Compound A 0.052 0.066 0.075 0.066
D-Methoxy Omeprazole 0.000 0.002 0.002 0.000
Omeprazole Related Compound-C 0.018 0.01 1 0.015 0.017
Highest Unknown 0.026 0.048 0.066 0.071
Total Unknown 0.175 0.346 0.460 0.394
Total RS 0.248 0.451 0.588 0.502
Table 8: Esomeprazole magnesium dihyc rate formulation o f Examp e 1 packed in Alu-Alu cold form Blister
The stability study results of the formulation of Example 1 indicates that, the it remains stable for a period of at least 3 months at 40 °C at 75% relative humidity, independent of the packaging. Further, total related substances were within the specified limits.
Example 6: Dissolution Study
The formulation of Example 1 was subjected to dissolution study using USP Type II (Paddle) dissolution apparatus at 100rpm after storing the formulation over 3 months at 40 °C and 75% relative humidity.
Table 9: Esomeprazole magnesium dihydrate formulation of Example 1 packed in 60cc HDPE container with CRC & 2 silica gel canisters
Table 10: Esomeprazole magnesium dihydrate formulation of Example 1 packed in Alu-Alu cold form Blister
Assay
Time
40°C/75%RH
(min) Initial
1 M 2 M 3 M
10 71 96 74 59
15 100 101 96 99
20 99 101 97 100
30 96 100 96 99
45 93 98 93 96
60 91 97 91 94
Claims
1 . A wet granulated pharmaceutical composition comprising esomeprazole magnesium dihydrate with one or more pharmaceutical excipients, wherein the composition is essentially free of esomeprazole magnesium trihydrate.
2. The wet granulated pharmaceutical composition of claim 1 , wherein the wet granulation comprises use of one or more solvents selected from di- lower alkyl ketone, acetone, ether, and diethyl ether.
3. The wet granulated pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable excipients comprises one or more of binders, plasticizer, fillers, lubricants, disintegrants, surfactants glidants and coating agents.
4. The wet granulated pharmaceutical composition of claim 2, wherein the binder comprise one or more of povidone, crospovidone or copolymer of N-vinyl-2-pyrrolidone and vinyl acetate starch, stearic acid, gums, hydroxypropylmethyl cellulose.
5. The wet granulated pharmaceutical composition of claim 2, wherein the plasticizer comprises one or more of dioctyl phthalate, dibutyl phthalate, benzylptyl phthalate or polyethelene glycol.
6. The wet granulated pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of pellets, a tablet, a capsule, granules, beads, a caplet, disc, pills, a sachet, spheroids, a minitablet, granules in a capsule, beads in a capsule and minitablets in a capsule.
7. The wet granulated pharmaceutical composition of claim 1 , wherein the composition exhibits controlled, extended, or delayed release of esomeprazole magnesium dihydrate.
8. A pharmaceutical composition comprising esomeprazole magnesium dihydrate with one or more pharmaceutical excipients prepared by a process comprising coating a mixture comprised of esomeprazole magnesium dihydrate and non-aqueous, non-alcoholic solvent on an inert core, wherein the composition is substantially free of esomeprazole magnesium trihydrate.
9. The pharmaceutical composition of claim 8, wherein the non-aqueous, non-alcoholic solvent comprises one or more of di-lower alkyl ketone, acetone, ether, and diethyl ether.
10. A process of preparing pharmaceutical composition of esomeprazole magnesium dihydrate, which process comprises of:
(a) mixing esomeprazole magnesium dihydrate with a binder soluble in non aqueous non-alcoholic solvent for granulation, optionally along with one or more pharmaceutically acceptable excipients;
(b) granulating the mixture prepared in step (a) by wet granulation process using a non-aqueous, non-alcoholic solvent as granulating liquid; and
(c) optionally, formulating the granules prepared in step (b) in a desired dosage form,
wherein the composition is essentially free of esomeprazole magnesium trihydrate.
1 1 . The process of claim 10, wherein the non-aqueous, non-alcoholic solvent comprises one or more of di-lower alkyl ketone, acetone, ether or diethyl ether.
12. The wet granulated pharmaceutical composition of claim 1 , wherein esomeprazole magnesium dihydrate in the composition provides an X-ray powder diffraction pattern exhibiting substantially the following d-values:
13. A method of treating a gastric acid related conditions which method comprises administering to a subject suffering from said condition the pharmaceutical composition of claim 1 .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3511MU2011 | 2011-12-14 | ||
| IN3511/MUM/2011 | 2011-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2013088272A1 true WO2013088272A1 (en) | 2013-06-20 |
Family
ID=47356240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2012/056089 WO2013088272A1 (en) | 2011-12-14 | 2012-11-01 | Pharmaceutical composition comprising esomeprazole magnesium dihydrate |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2013088272A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022154687A1 (en) * | 2021-01-14 | 2022-07-21 | Общество C Ограниченной Ответственностью "Новамедика" | Pharmaceutical composition containing esomeprazole |
| RU2811593C1 (en) * | 2021-01-14 | 2024-01-15 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Pharmaceutical composition, including esomeprazole (embodiments), oral dosage form based on pharmaceutical composition, including esomeprazole, method for production and application of oral dosage form based on pharmaceutical composition containing ezomeprazole |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998054171A1 (en) * | 1997-05-30 | 1998-12-03 | Astra Aktiebolag | Novel form of s-omeprazole |
| WO2008092939A2 (en) * | 2007-01-31 | 2008-08-07 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation |
| WO2009060064A2 (en) * | 2007-11-09 | 2009-05-14 | Valpharma S.A. | Pharmaceutical formulations for the oral administration of ppi |
| EP2147918A1 (en) * | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
| WO2011144994A1 (en) * | 2010-05-21 | 2011-11-24 | Lupin Limited | Pharmaceutical compositions of nsaid and acid inhibitor |
-
2012
- 2012-11-01 WO PCT/IB2012/056089 patent/WO2013088272A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998054171A1 (en) * | 1997-05-30 | 1998-12-03 | Astra Aktiebolag | Novel form of s-omeprazole |
| US7411070B2 (en) | 1997-05-30 | 2008-08-12 | Astrazeneca Ab | Form of S-omeprazole |
| WO2008092939A2 (en) * | 2007-01-31 | 2008-08-07 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation |
| WO2009060064A2 (en) * | 2007-11-09 | 2009-05-14 | Valpharma S.A. | Pharmaceutical formulations for the oral administration of ppi |
| EP2147918A1 (en) * | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
| WO2011144994A1 (en) * | 2010-05-21 | 2011-11-24 | Lupin Limited | Pharmaceutical compositions of nsaid and acid inhibitor |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022154687A1 (en) * | 2021-01-14 | 2022-07-21 | Общество C Ограниченной Ответственностью "Новамедика" | Pharmaceutical composition containing esomeprazole |
| RU2811593C1 (en) * | 2021-01-14 | 2024-01-15 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Pharmaceutical composition, including esomeprazole (embodiments), oral dosage form based on pharmaceutical composition, including esomeprazole, method for production and application of oral dosage form based on pharmaceutical composition containing ezomeprazole |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2214232C2 (en) | Prolonged-release oral pharmaceutical medicinal form | |
| KR102090242B1 (en) | Oral pharmaceutical compositions of dabigatran etexilate | |
| CA2529984C (en) | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors | |
| PL192437B1 (en) | Pharmaceutical formulation comprising a 2- [[(2- pyridinyl) methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation | |
| JPWO2007074909A1 (en) | Controlled release solid formulation | |
| JPWO2007074910A1 (en) | Controlled release solid formulation | |
| US20150209432A1 (en) | Pharmaceutical compositions of proton pump inhibitor | |
| CA2851327C (en) | Coated pellets of omeprazole | |
| WO2010122583A2 (en) | Oral pharmaceutical compositions of acid labile substances | |
| WO2012001705A2 (en) | Pharmaceutical compositions of (r)-lansoprazole | |
| WO2011140446A2 (en) | Pharmaceutical formulations | |
| KR20070083956A (en) | New Modified Release Tablet Formulations for Proton Pump Inhibitors | |
| WO2017184566A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| WO2011025673A1 (en) | Multilayer minitablets | |
| WO2010041276A1 (en) | Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof | |
| EP2533766A2 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
| EP2313088A2 (en) | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer | |
| JP2014508187A (en) | Controlled release pharmaceutical composition of selective serotonin reuptake inhibitor | |
| WO2005034924A1 (en) | Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation | |
| WO2013088272A1 (en) | Pharmaceutical composition comprising esomeprazole magnesium dihydrate | |
| WO2004066982A1 (en) | Stable oral benzimidazole compositions and processes for their preparation | |
| CA3160869C (en) | Dosage form for use in treating or preventing of a disease | |
| EP2081546A2 (en) | Multiple unit tablet compositions of benzimidazole compounds | |
| JP2013536832A (en) | Milnacipran controlled release pharmaceutical composition | |
| WO2010018593A2 (en) | Gastric acid resistant benzimidazole multiple unit tablet composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12799618 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12799618 Country of ref document: EP Kind code of ref document: A1 |